The development of TAAR1 ligands represents an intriguing strategy for the treatment of several disorders including schizophrenia, depression, attention deficit hyperactivity disorder, Parkinson’s disease, addiction, and metabolic diseases [22]. Here, TAAR1 is linked to depressive symptom measurement.